Last reviewed · How we verify
EDG-7500
At a glance
| Generic name | EDG-7500 |
|---|---|
| Sponsor | Edgewise Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate EDG-7500 in People With Renal Impairment (PHASE1)
- A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment (PHASE1)
- A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults (PHASE1)
- A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) (PHASE2)
- A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500 (PHASE1)
- A Study of EDG-7500 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EDG-7500 CI brief — competitive landscape report
- EDG-7500 updates RSS · CI watch RSS
- Edgewise Therapeutics, Inc. portfolio CI